The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as threats ...

Minot Light Capital, an investment management firm, recently released its fourth-quarter 2024 investor letter. A copy of the ...

Bullish option flow detected in GSK (GSK) Pharma with 3,057 calls trading, 1.1x expected, and implied vol increasing over 4 points to 29.80%. Feb-25 34 calls and 1/31 weekly 34 calls are the most ...

The CEO of Germany's Merck KGaA on Thursday said a recovery in sales growth at its existing business means it can take a ...

Financial writer analysis of Arcutis Biotherapeutics, Inc. stock surge and potential growth, FDA approvals, and partnerships ...

Is BioMarin stock a bargain or a falling knife? Learn about key issues affecting its investment prospects and potential for recovery.

Johnson & Johnson ( JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...

Johnson & Johnson , fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular , reported fourth-quarter ...

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported its third-quarter 2024 earnings, highlighting a steady increase in revenue and strategic developments in product innovation and market expansion. Despite ...